A single-dose of Trogenix’s proprietary Synthetic Super-Enhancers achieved complete tumour elimination in 83% of treated cases with no toxicity over 11 months and no tumour recurrence in a brain ...
Nuvalent seeks FDA approval of neladalkib for TKI-pretreated advanced ALK-positive NSCLC, leveraging ALKOVE-1 results demonstrating activity in extracranial disease and brain metastases. ALKOVE-1 ...
A positive phase three trial result in a hard-to-treat cancer adds fresh momentum to one of AstraZeneca's most important ...
After more than a decade of living with Parkinson’s, Rebecca Crews is opening up about her diagnosis and a new ...
A major event aimed at raising awareness and funding cancer research in Arkansas is coming up this weekend.The 6th Annual Be ...
Advanced Urology founder Dr. Jitesh Patel brings histotripsy to Atlanta — a non-invasive, scalpel-free breakthrough for ...
OpenAI CEO Sam Altman says a man used ChatGPT to create a personalised cancer vaccine for his dog, highlighting AI’s ...
Discover how advanced radiation and targeted therapies are transforming nasopharyngeal cancer care in India. Expert insights ...
Dupixent (dupilumab) has been a genuine breakthrough for many families. For children with moderate-to-severe eczema, asthma, ...
A young woman with advanced, inoperable tongue cancer experienced a rare recovery after immunotherapy and chemotherapy.
Alphamab Oncology (stock code: 9966.HK) today announced that HER2 bispecific antibody Anbenitamab Injection (KN026), independently developed by the Company, and co-developed with JMT-Bio Technology Co ...
CAR-T therapy works by taking a patient's immune cells, modifying them in a lab to better recognise cancer, and then infusing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results